Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights

Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent single-gene disorder leading to renal failure. Current therapies are aimed to treat renal and extrarenal complications of ADPKD, but improved knowledge of the pathophysiological mechanisms leading to the generation and growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Carullo, Nazareno, Zicarelli, Maria Teresa, Casarella, Alessandro, Nicotera, Ramona, Castagna, Alberto, Urso, Alessandra, Presta, Pierangela, Andreucci, Michele, Russo, Emilio, Bolignano, Davide, Coppolino, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473846/
https://www.ncbi.nlm.nih.gov/pubmed/34588803
http://dx.doi.org/10.2147/IJGM.S305491
_version_ 1784575084886753280
author Carullo, Nazareno
Zicarelli, Maria Teresa
Casarella, Alessandro
Nicotera, Ramona
Castagna, Alberto
Urso, Alessandra
Presta, Pierangela
Andreucci, Michele
Russo, Emilio
Bolignano, Davide
Coppolino, Giuseppe
author_facet Carullo, Nazareno
Zicarelli, Maria Teresa
Casarella, Alessandro
Nicotera, Ramona
Castagna, Alberto
Urso, Alessandra
Presta, Pierangela
Andreucci, Michele
Russo, Emilio
Bolignano, Davide
Coppolino, Giuseppe
author_sort Carullo, Nazareno
collection PubMed
description Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent single-gene disorder leading to renal failure. Current therapies are aimed to treat renal and extrarenal complications of ADPKD, but improved knowledge of the pathophysiological mechanisms leading to the generation and growth of cysts has permitted the identification of new drug candidates for clinical trials. Among these, in this review, we will examine above all the role of metformin, hypothesized to be able to activate the AMP-activated protein kinase (AMPK) pathway and potentially modulate some mechanisms implicated in the onset and the growth of the cysts.
format Online
Article
Text
id pubmed-8473846
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84738462021-09-28 Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights Carullo, Nazareno Zicarelli, Maria Teresa Casarella, Alessandro Nicotera, Ramona Castagna, Alberto Urso, Alessandra Presta, Pierangela Andreucci, Michele Russo, Emilio Bolignano, Davide Coppolino, Giuseppe Int J Gen Med Review Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent single-gene disorder leading to renal failure. Current therapies are aimed to treat renal and extrarenal complications of ADPKD, but improved knowledge of the pathophysiological mechanisms leading to the generation and growth of cysts has permitted the identification of new drug candidates for clinical trials. Among these, in this review, we will examine above all the role of metformin, hypothesized to be able to activate the AMP-activated protein kinase (AMPK) pathway and potentially modulate some mechanisms implicated in the onset and the growth of the cysts. Dove 2021-09-22 /pmc/articles/PMC8473846/ /pubmed/34588803 http://dx.doi.org/10.2147/IJGM.S305491 Text en © 2021 Carullo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Carullo, Nazareno
Zicarelli, Maria Teresa
Casarella, Alessandro
Nicotera, Ramona
Castagna, Alberto
Urso, Alessandra
Presta, Pierangela
Andreucci, Michele
Russo, Emilio
Bolignano, Davide
Coppolino, Giuseppe
Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights
title Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights
title_full Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights
title_fullStr Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights
title_full_unstemmed Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights
title_short Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights
title_sort retarding progression of chronic kidney disease in autosomal dominant polycystic kidney disease with metformin and other therapies: an update of new insights
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473846/
https://www.ncbi.nlm.nih.gov/pubmed/34588803
http://dx.doi.org/10.2147/IJGM.S305491
work_keys_str_mv AT carullonazareno retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT zicarellimariateresa retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT casarellaalessandro retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT nicoteraramona retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT castagnaalberto retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT ursoalessandra retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT prestapierangela retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT andreuccimichele retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT russoemilio retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT bolignanodavide retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights
AT coppolinogiuseppe retardingprogressionofchronickidneydiseaseinautosomaldominantpolycystickidneydiseasewithmetforminandothertherapiesanupdateofnewinsights

Ejemplares similares